Mymetics (MYMX) Stock Price, News & Analysis

Company Overview

Mymetics (OTCMKTS: MYMX) is a clinical-stage biotechnology company specializing in the development of prophylactic and therapeutic vaccines for infectious diseases. The company’s proprietary virosome‐based delivery platform is designed to present antigens in a lipid bilayer, mimicking the natural presentation of viruses to the immune system. This approach aims to stimulate robust and durable humoral and cellular responses while maintaining a favorable safety profile.

The company’s pipeline includes candidates targeting viral pathogens such as influenza, herpes simplex virus (HSV), and human immunodeficiency virus (HIV). Mymetics’ lead programs have advanced through preclinical and early‐stage clinical evaluations, demonstrating proof of concept for its virosome technology. Additional research collaborations have explored applications in pandemic preparedness and emerging infectious diseases.

Founded in 1998, Mymetics is headquartered in Belgium with a subsidiary in the United States to support North American development and regulatory activities. The company has focused on leveraging its virosome platform to form strategic partnerships, aiming to accelerate late‐stage clinical trials and commercialization efforts. Its management team comprises professionals with experience in vaccine research, clinical development, and regulatory affairs, guiding the company’s strategic direction in global markets.

Key Stats

• Today's Range: $0.0003 to $0.0003
• 50-Day Range: N/A
• 52-Week Range: $0.0003 to $0.0003
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: $45.00
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MYMX Stock Analysis - Frequently Asked Questions

How have MYMX shares performed this year?

Mymetics' stock was trading at $0.0010 at the beginning of the year. Since then, MYMX stock has decreased by 70.0% and is now trading at $0.0003.

How do I buy shares of Mymetics?

Shares of MYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Mymetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Mymetics investors own include Dynavax Technologies (DVAX), Fujitsu (FJTSY), Genocea Biosciences (GNCA), Maxar Technologies (MAXR), Revance Therapeutics (RVNC), Axcelis Technologies (ACLS) and Allied Gaming & Entertainment (AGAE).

Company Calendar

• Today: 9/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:MYMX
• CIK: 927761
• Web: www.mymetics.com
• Phone: (121) 653-4535
• Fax: 41-21-653-2473
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $1.08 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 150,000
• Free Float: 144,000
• Market Cap: $45.00
• Optionable: Not Optionable
• Beta: 2.43